Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): Results from GeparSixto.

被引：0
|
作者：
Von Minckwitz, Gunter
Hahnen, Eric
Fasching, Peter A.
Hauke, Jan
Schneeweiss, Andreas
Salat, Christoph
Rezai, Mandi
Blohmer, Jens U.
Zahm, Dirk Michael
Jackisch, Christian
Gerber, Bernd
Klare, Peter
Kummel, Sherko
Eidtmann, Holger
Paepke, Stefan
Nekljudova, Valentina
Le Loibl, Sibyl
Untch, Michael
Schmutzler, Rita K.
机构：
[1] Goethe Univ Frankfurt, German Breast Grp, D-60054 Frankfurt, Germany
[2] Univ Cologne, D-50931 Cologne, Germany
[3] Univ Erlangen Nurnberg, Dept Obstet & Gynecol, Univ Hosp Erlangen, Comprehens Canc Ctr Erlangen EMN, D-91054 Erlangen, Germany
[4] Univ Heidelberg Hosp, Heidelberg, Germany
[5] Hematol Oncol Clin, Munich, Germany
[6] Louisen Hosp, Breast Ctr Duesseldorf, Dusseldorf, Germany
[7] Brustzentrum Sankt Gertrauden Krankenhaus, Berlin, Germany
[8] Frauenklin Gera, Gera, Germany
[9] Sana Kliniken Offenbach, Offenbach, Germany
[10] Univ Rostock, D-18055 Rostock, Germany
[11] Praxisklin Krebsheilkunde, Berlin, Germany
[12] Evangel Huyssens Stiftung, Kliniken Essen Mitte, Breast Canc Ctr, Essen, Germany
[13] Univ Kiel, Kiel, Germany
[14] Tech Univ Munich, Klinikum Rechts Isar, Dept Obstet & Gynecol, D-80290 Munich, Germany
[15] German Breast Grp, Neu Isenburg, Germany
[16] Sana Klinikurn Offenbach, German Breast Grp, Neu Isenburg, Germany
[17] Helios Klinikum Berlin Buch, Dept Gynecol & Obstet, Berlin, Germany
[18] Helios Klinikum Berlin Buch, Multidisciplinary Breast Canc Ctr, Berlin, Germany
[19] Ctr Familial Breast & Ovarian Canc, Cologne, Germany
[20] Ctr Integrated Oncol, Cologne, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1005
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Association of gut microbiome diversity and composition with pathological complete response (pCR) after neoadjuvant chemotherapy in triple negative breast cancer
    Vernaci, G.
    Cumerlato, E.
    Griguolo, G.
    Massa, D.
    Menichetti, A.
    Miglietta, F.
    Tasca, G.
    Savarino, E.
    Conte, P. F.
    Guarneri, V.
    Dieci, M. V.
    ANNALS OF ONCOLOGY, 2020, 31 : S50 - S50
  • [32] Association of pathological complete response rates and TILs in triple-negative breast cancer patients.
    Kassem, Mahmoud
    Goldstein, Daniel
    Schnell, Patrick
    Grimm, Michael
    Quiroga, Dionisia Marie
    Miah, Abdul
    Vargo, Craig
    Shinde, Namrata Vilas
    Michael, Berger
    Pariser, Ashley
    Gatti-Mays, Margaret Elena
    VanDeusen, Jeffrey Bryan
    Williams, Nicole Olivia
    Stover, Daniel G.
    Sardesai, Sagar D.
    Wesolowski, Robert
    Lustberg, Maryam B.
    Ramaswamy, Bhuvaneswari
    Tozbikian, Gary
    Cherian, Mathew Amprayil
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [33] Pathologic complete response (pCR) to neoadjuvant treatment (NAT) with carboplatin, nab-paclitaxel and anthracycline in early and locally advanced triple-negative breast cancer (TNBC).
    Miras, Isabel
    Gil, Ana
    Santos-Fernandez, Paloma
    Sanchez-Camacho, Alberto
    Falcon Gonzalez, Alejandro
    Benavent, Marta
    Cejuela Solis, Monica
    Bofill, Salvador
    Flores, Sandra
    Ruiz-Borrego, Manuel
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [34] Pathological tumor response to neoadjuvant chemotherapy using anthracycline and taxanes in patients with triple-negative breast cancer
    Sakuma, Kaori
    Kurosumi, Masafumi
    Oba, Hanako
    Kobayashi, Yasuhito
    Takei, Hiroyuki
    Inoue, Kenichi
    Tabei, Toshio
    Oyama, Tetsunari
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2011, 2 (02) : 257 - 264
  • [35] Pathological complete response rates in patients with BRCA1/2-associated breast cancer after neoadjuvant chemotherapy
    Richters, L.
    Rhiem, K.
    Wappenschmidt, B.
    Kiechle, M.
    Schmutzler, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 13 - 14
  • [36] Disparities Influence Pathologic Complete Response Rates After Neoadjuvant Chemotherapy In Triple Negative Breast Cancer
    Calvo, C.
    Colton, A.
    Hester, C. A.
    Xu, X.
    Zhu, H.
    Partain, N. S.
    Wooldridge, R.
    Farr, D.
    Huth, J.
    Leitch, M.
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 : S101 - S101
  • [37] Pathological complete response following cisplatin or carboplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: A systematic review and meta-analysis
    Vidra, Radu
    Nemes, Adina
    Vidrean, Andreea
    Pintea, Sebastian
    Tintari, Snejeana
    Deac, Andrada
    Ciuleanu, Tudor
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2022, 23 (01)
  • [38] Pathological complete response (pCR) association with a novel homologous recombination deficiency HRD signature (HRDsig) in patients with triple-negative breast cancer (TNBC) receiving neoadjuvant therapy (Tx)
    Gupta, Tanya
    Graf, Ryon P.
    Schrock, Alexa B.
    Madison, Russell
    Ross, Jeffrey S.
    Levy, Mia Alyce
    Quintanilha, Julia
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] Prognostic function of Ki-67 for pathological complete response rate of neoadjuvant chemotherapy in triple-negative breast cancer
    Zhang, Guojing
    Xie, Wanqing
    Liu, Zhaozhe
    Lin, Chao
    Piao, Ying
    Xu, Long
    Guo, Fang
    Xie, Xiaodong
    TUMORI JOURNAL, 2014, 100 (02): : 136 - 142
  • [40] Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Pairwise and Network Meta-Analysis of Pathological Complete Response
    Weng, Zeng-Jie
    Wu, Sheng-Xi
    Luo, He-San
    Du, Ze-Sen
    Li, Xu-Yuan
    Lin, Jia-Zhou
    INQUIRY-THE JOURNAL OF HEALTH CARE ORGANIZATION PROVISION AND FINANCING, 2021, 58
12345